黄金纳米集群和人体血清白蛋白之间的结构-活性关系:连接物异构化的效应
概括
金纳米集群 (AuNCs) 上的连接物异构化显著影响它们与像人血清白蛋白 (HSA) 这样的蛋白质的相互作用. 了解这些差异指导未来的金属纳米集群应用.
科学领域:
- 纳米材料科学 科学 纳米材料科学
- 生物化学 生物化学
- 蛋白质 - 连接体相互作用
背景情况:
- 金纳米集群 (AuNCs) 和蛋白质相互作用得到了广泛的研究.
- 配体异构对AuNC-蛋白质结构-活性关系的影响尚不清楚.
研究的目的:
- 为了分析Au25纳米集群与不同的mercaptobenzoic酸异构体 (p/m/o-MBA-Au25NCs) 和人血清白蛋白 (HSA) 修饰之间的相互作用.
- 阐明连接物异构化对结合特性和蛋白质稳定性的影响.
主要方法:
- 使用多谱分析研究了p/m/o-MBA-Au25NCs与HSA的结合.
- 评估了热力学参数,结合强度,驱动力和结合比.
主要成果:
- 这三种修改后的Au25NC都与HSA的I位点结合,通过动态相互作用增强其稳定性.
- 在这三种异构体中,观察到结合强度,热力学,驱动力和固态度的显著变化.
- 配体的不同极性和异构形式影响了HSA.中氨基酸残留的微环境.
结论:
- 在AuNCs上的联结体同质化极大地影响了它们与蛋白质的相互作用.
- 这项研究为在生物应用中选择合适的金属纳米集群的配体提供了理论指导.
相关概念视频
Factors Affecting Protein-Drug Binding: Drug-Related Factors
96
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
96
Factors Affecting Protein-Drug Binding: Protein-Related Factors
150
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
150
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Ligand Binding Sites
12.8K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.8K
Drug Distribution: Plasma Protein Binding
5.5K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.5K


